# Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

> **NCT04365985** · PHASE2 · TERMINATED · sponsor: **Corewell Health East** · enrollment: 70 (actual)

## Conditions studied

- COVID-19
- Acute Respiratory Distress Syndrome
- Severe Acute Respiratory Syndrome (SARS)
- Coronavirus Infections

## Interventions

- **DRUG:** Naltrexone
- **DRUG:** Ketamine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04365985
- **Lead sponsor:** Corewell Health East
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-29
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Because of the decrease in COVID cases, enrollment is extremely low. Given the current study design, it is not possible to gather data necessary to answer the question about whether study treatment reduces mortality
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04365985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04365985, "Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04365985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*